NCT01289132 - Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension | Biotech Hunter

Enrollment

926

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Essential Hypertension

Interventions

DRUG

Placebo

Placebo-matching tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Azilsartan

Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Candesartan cilexetil

Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.